European Medicines Agency approves pembrolizumab plus axitinib for first-line treatment of advanced kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of [...]
Outcomes of metastatic kidney cancer patients treated with first-line immunotherapy and second-line VEGFR-TKI
The standard of care recommended for the treatment of patients [...]
Outcomes following partial nephrectomy and percutaneous ablation for small renal masses
A study published in European Urology presents retrospective data from [...]
Extended duration of active surveillance of small renal masses
A recent study published in the Journal of Urology evaluated [...]
European Association of Urology renal cell carcinoma guidelines updated
The European Association of Urology (EAU) renal cell carcinoma (RCC) [...]
Role of stereotactic ablative radiotherapy for primary renal cell carcinoma
This paper reviews the use of stereotactic ablative radiotherapy (SABR) [...]
Long term survival of patients with metastatic kidney cancer – a real world study
This real world study reports on the long term survival [...]
Developments in data for rare and less common cancers
Cancer52 and the National Cancer Registration and Analysis Service (NCRAS) [...]
Avelumab plus axitinib combination available via EAMS
It has just been announced that the avelumab plus axitinib [...]
Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer
A recent study, published in Clinical Genitourinary Cancer reports a [...]
